Heart Disease & Cardiology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

This study is testing whether giving a half-dose of recombinant staphylokinase, a clot-busting medicine, before a standard heart procedure called primary PCI can help people who have a severe type of heart attack known as STEMI. The goal is to reduce heart damage and improve recovery after the heart attack. This large trial in China is following over 2,000 patients for 90 days to see if this approach can offer a safer and more effective treatment during emergency care.

Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease

This trial is exploring the safety and effectiveness of the drug empagliflozin for patients who have heart failure with reduced pumping ability and also have severe kidney failure requiring dialysis. Because treatment options are limited for patients with both heart and kidney problems, this study in Taiwan aims to find out if empagliflozin can improve heart health and quality of life for these patients. About 95 participants are being followed closely during the study.

CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome

This research focuses on patients with acute coronary syndrome and serious kidney disease, testing whether the medication dapagliflozin can reduce inflammation around heart arteries. Since inflammation contributes to heart disease progression, this treatment could slow worsening heart problems with a simple daily pill. The study in China is following patients for six months to understand how the drug affects heart artery health.

Heart Failure Patient Management and Interventions Using Continuous Patient Monitoring Outside Hospitals and Real-world Data

This study is testing a digital monitoring system that collects health data continuously from patients with chronic heart failure, heart transplants, or heart assist devices. By providing doctors with real-time information, the system aims to improve treatment decisions, reduce hospital visits, and enhance patients’ quality of life. The trial is taking place in several European countries and lasts 18 months, involving regular check-ins.

The Effect of Remimazolam Tosylate on the Incidence of Postoperative Delirium in Older Patients Undergoing Cardiac Surgery: A Prospective Randomized Controlled Trial

This trial compares two sedative drugs to find out which one better prevents confusion and memory problems after heart surgery in patients aged 65 and older. Postoperative delirium is common and can affect recovery, so discovering a safer sedation method could improve outcomes for older adults. This study in China plans to enroll 600 patients and will share results after surgery follow-up.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.